✨ Free AI Report
RenovoRx, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research RenovoRx, Inc.
Company Research

RenovoRx, Inc.: Business Overview, Financials & Competitive Analysis

RenovoRx, Inc. is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeti...

Analyst-debate audio for RenovoRx, Inc.

AskCyborg analysts argue the bull and bear cases for RenovoRx, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Early-stage oncology device/pharma platform with FDA clearance, strong IP, and expanding commercial traction in underserved solid...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest RenovoRx, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

RenovoRx, Inc. Overview

Pro stress-test →

RenovoRx, Inc. is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Strategic Profile

Pro stress-test →

RenovoRx achieved key milestones in the commercial launch of RenovoCath in 2025, its first full year of generating revenue with a growing adoption of TAMP enabled by RenovoCath in cancer centers throughout the United States, with early commercial traction reflecting increasing physician interest in targeted intra-arterial drug-delivery. RenovoRx estimates that the initial total addressable market (TAM) for RenovoCath as a stand-alone device represents an approximately $400 million peak annual U.S. sales opportunity, and ultimately a multi-billion-dollar potential as the platform expands into additional solid tumor indications.

Competitive Landscape

Pro stress-test →

RenovoRx competes in the targeted combination therapies and drug delivery device space, with its lead product RenovoCath providing chemotherapy gemcitabine through targeted intra-arterial delivery in Phase III clinical trials for locally advanced pancreatic cancer. Direct competitors in localized oncology drug delivery and pancreatic cancer treatment include established players like Varian (radiotherapy), Ono Pharmaceutical, and various systemic chemotherapy providers.

Industry Context

RenovoRx, Inc. operates in Oncology Drugs.

Key facts

Founded: 2009 · Headquarters: Mountain View, US · Revenue: $1.1M · Market cap: $41.4M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on RenovoRx, Inc..

  • The RenovoTAMP therapy is being studied in the Phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer.
  • In its first full year of commercial efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales with several customers already initiating repeat orders and the number of medical institutions initiating new RenovoCath orders expanding, including several esteemed, high-volume National Cancer Institute-designated centers.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Pharmacokinetic and pharmacodynamic data abstract accepted for presentation at 2026 ASCO Annual Meeting
  • April 2026Named to Fast Company's World's Most Innovative Companies 2026 list (medical device category rank: 10)
  • +1 moreTrack every material event for RenovoRx, Inc. as it happens. Explore monitoring →
Get alerted when RenovoRx, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

VarianRadiation therapy for cancer treatment→Gemcitabine (Systemic)Standard systemic chemotherapy for pancreatic cancer→FOLFIRINOXMulti-drug systemic chemotherapy regimen→

Compare RenovoRx, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

RenovoRx, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about RenovoRx, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare RenovoRx, Inc. and its top competitor on Cyborg Score”
“What did RenovoRx, Inc. do this quarter?”
“Is RenovoRx, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does RenovoRx, Inc. do?+
RenovoRx, Inc. is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeti...
What is RenovoRx, Inc.'s Cyborg Score?+
RenovoRx, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are RenovoRx, Inc.'s main competitors?+
Named competitors include Varian, Gemcitabine (Systemic), FOLFIRINOX. The full competitive landscape is in the AskCyborg report.
How can I get the full RenovoRx, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the RenovoRx, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track RenovoRx, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.